logo
#

Latest news with #PINC

Nuclear's next chapter: EU charts EUR241bn path to decarbonised energy future
Nuclear's next chapter: EU charts EUR241bn path to decarbonised energy future

Gulf Business

time10 hours ago

  • Business
  • Gulf Business

Nuclear's next chapter: EU charts EUR241bn path to decarbonised energy future

Image courtesy: WAM/ For illustrative purposes As Europe accelerates its green transition, the European Commission has laid out an ambitious roadmap that positions nuclear energy as a central pillar of its long-term decarbonisation strategy. According to the latest The report underscores a critical message: nuclear power is not fading — it's evolving. While public opinion and national energy policies remain divided, the EU's projections signal a net increase in nuclear capacity, from 98GW today to 109 GW by 2050, with an upper-range scenario anticipating up to 144GW. Nuclear energy a bedrock Currently accounting for 23 per cent of the EU's electricity mix, nuclear energy remains a bedrock of low-carbon power generation. Yet, the landscape is fragmented: countries like Germany and Belgium are phasing out nuclear, while others — such as France, Hungary, and Finland — are doubling down on next-generation reactors and small modular reactors (SMRs). The PINC report acknowledges this diversity but calls for greater alignment and infrastructure investment to realise the collective benefits of nuclear. EU aims to be decarbonised by 2040 Looking ahead, over 90 per cent of Europe's electricity is expected to be decarbonised by 2040. Achieving this milestone, the commission argues, will require nuclear to complement intermittent renewables like wind and solar by offering stable baseload power. As energy demand rises with the electrification of transport, heating, and industry, the resilience of nuclear becomes even more vital. However, the scale of investment required is daunting. To bridge the funding gap, the commission urges a blended financing model that leverages both public and private capital, coupled with risk-mitigation mechanisms to improve investor confidence. These could include loan guarantees, state aid frameworks, and EU-backed financial instruments tailored to large-scale nuclear projects. While the debate over nuclear's role in a clean energy future continues, the EU's latest projections make one thing clear: without nuclear, Europe's path to net zero will be longer, costlier, and less secure. As the bloc confronts geopolitical instability, energy price volatility, and climate urgency, the commission's blueprint stakes a bold claim: a decarbonised Europe will be part nuclear-powered — or not at all. Read:

1 Mooning Stock on Our Buy List and 2 to Be Wary Of
1 Mooning Stock on Our Buy List and 2 to Be Wary Of

Yahoo

time03-06-2025

  • Business
  • Yahoo

1 Mooning Stock on Our Buy List and 2 to Be Wary Of

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. However, not all companies with momentum are long-term winners, and many investors have lost money by following short-term trends. All that said, here is one stock we think lives up to the hype and two not so much. One-Month Return: +8.6% Originally formed in 1988 as part of Bell Labs, Commvault (NASDAQ: CVLT) provides enterprise software used for data backup and recovery, cloud and infrastructure management, retention, and compliance. Why Do We Think Twice About CVLT? Sales trends were unexciting over the last three years as its 9% annual growth was well below the typical software company Expenses have increased as a percentage of revenue over the last year as its operating margin fell by 1.6 percentage points At $189 per share, Commvault Systems trades at 7.5x forward price-to-sales. Read our free research report to see why you should think twice about including CVLT in your portfolio, it's free. One-Month Return: +11.5% Operating one of the largest healthcare group purchasing organizations in the United States with over 4,350 hospital members, Premier (NASDAQ:PINC) is a technology-driven healthcare improvement company that helps hospitals, health systems, and other providers reduce costs and improve clinical outcomes. Why Do We Pass on PINC? Sales tumbled by 9.3% annually over the last two years, showing market trends are working against its favor during this cycle Sales are projected to tank by 10.6% over the next 12 months as its demand continues evaporating Falling earnings per share over the last five years has some investors worried as stock prices ultimately follow EPS over the long term Premier's stock price of $22.86 implies a valuation ratio of 17x forward P/E. Dive into our free research report to see why there are better opportunities than PINC. One-Month Return: +6.4% Started by Peter Thiel after seeing US defence agencies struggle in the aftermath of the 2001 terrorist attacks, Palantir (NYSE:PLTR) offers software as a service platform that helps government agencies and large enterprises use data to make better decisions. Why Is PLTR a Good Business? Average billings growth of 38.6% over the last year enhances its liquidity and shows there is steady demand for its products Fast payback periods on sales and marketing expenses allow the company to invest heavily and onboard many customers concurrently Strong free cash flow margin of 47.2% enables it to reinvest or return capital consistently Palantir is trading at $131.63 per share, or 81.2x forward price-to-sales. Is now the time to initiate a position? See for yourself in our full research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.

Premier Has Stable Business But Analyst Remains Neutral - Here's Why
Premier Has Stable Business But Analyst Remains Neutral - Here's Why

Yahoo

time04-04-2025

  • Business
  • Yahoo

Premier Has Stable Business But Analyst Remains Neutral - Here's Why

J.P. Morgan analyst Anne E. Samuel reiterated the Neutral rating on Premier, Inc. (NASDAQ:PINC) on Tuesday, with a price forecast of $19. The analyst notes that Premier's stable business is supported by its ownership structure, leading to longer-term contracts typically lasting five to seven years. Meanwhile, the company's growth is closely tied to hospital utilization trends, which has historically led to an expected long-term growth rate of mid-single-digit to high-single-digit percentage increases in both revenue and profit, Samuel adds. In the short term, though, Premier has experienced weaker performance due to factors like the end of COVID-related stockpiling, rising inflation, and budget constraints faced by hospitals. Also Read: The analyst highlights several risks that could lead to PINC shares underperforming compared to others. These risks include a potential slowdown in growth within the Group Purchasing Organization business, due to a weak macroeconomic environment, reduced hospital utilization, and the increasing trend of hospitals forming their own GPOs, as well as heightened competition in the market, the analyst cautions. Additionally, Samuel adds that the Performance Services business faces significant competition, particularly from larger companies with more capital. Meanwhile, if hospital utilization trends improve, growth could accelerate, potentially making the analyst's current estimates and price target too low, Samuel notes. Price Action: PINC shares are trading higher by 0.05% to $19.49 at last check Wednesday. Read now:Image via Shutterstock. Date Firm Action From To Aug 2021 Raymond James Maintains Outperform Aug 2021 SVB Leerink Maintains Outperform May 2021 Barclays Downgrades Overweight Underweight View More Analyst Ratings for PINC View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? PREMIER (PINC): Free Stock Analysis Report This article Premier Has Stable Business But Analyst Remains Neutral - Here's Why originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio

1 Stock Under $50 on Our Watchlist and 2 to Turn Down
1 Stock Under $50 on Our Watchlist and 2 to Turn Down

Yahoo

time31-03-2025

  • Business
  • Yahoo

1 Stock Under $50 on Our Watchlist and 2 to Turn Down

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they're not immune to volatility as many lack the scale advantages of their larger peers. Luckily for you, our mission at StockStory is to help you make money and avoid losses by sorting the winners from the losers. That said, here is one stock under $50 with huge potential and two best left ignored. Share Price: $39.18 Operating as a critical behind-the-scenes partner for complex technology products since 1979, Benchmark Electronics (NYSE:BHE) provides advanced manufacturing, engineering, and technology solutions for original equipment manufacturers across aerospace, medical, industrial, and technology sectors. Why Should You Dump BHE? Customers postponed purchases of its products and services this cycle as its revenue declined by 4.1% annually over the last two years Low free cash flow margin of 0.6% for the last five years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders Low returns on capital reflect management's struggle to allocate funds effectively Benchmark's stock price of $39.18 implies a valuation ratio of 16x forward price-to-earnings. Check out our free in-depth research report to learn more about why BHE doesn't pass our bar. Share Price: $18.06 Operating one of the largest healthcare group purchasing organizations in the United States with over 4,350 hospital members, Premier (NASDAQ:PINC) is a technology-driven healthcare improvement company that helps hospitals, health systems, and other providers reduce costs and improve clinical outcomes. Why Are We Out on PINC? Products and services are facing significant end-market challenges during this cycle as sales have declined by 6.9% annually over the last two years Sales are projected to tank by 15.9% over the next 12 months as its demand continues evaporating Waning returns on capital from an already weak starting point displays the inefficacy of management's past and current investment decisions Premier is trading at $18.06 per share, or 15.2x forward price-to-earnings. Read our free research report to see why you should think twice about including PINC in your portfolio, it's free. Share Price: $27.65 Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE:HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products. Why Is HIMS on Our Radar? Customer trends over the past two years show it's maintaining a steady flow of new contracts that can potentially increase in value over time Free cash flow margin expanded by 17.9 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends Rising returns on capital show the company is starting to reap the benefits of its past investments At $27.65 per share, Hims & Hers Health trades at 28.6x forward price-to-earnings. Is now the right time to buy? See for yourself in our comprehensive research report, it's free. With rates dropping, inflation stabilizing, and the elections in the rearview mirror, all signs point to the start of a new bull run - and we're laser-focused on finding the best stocks for this upcoming cycle. Put yourself in the driver's seat by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Sterling Infrastructure (+1,096% five-year return). Find your next big winner with StockStory today for free.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store